JP2021519763A5 - - Google Patents
Info
- Publication number
- JP2021519763A5 JP2021519763A5 JP2020552294A JP2020552294A JP2021519763A5 JP 2021519763 A5 JP2021519763 A5 JP 2021519763A5 JP 2020552294 A JP2020552294 A JP 2020552294A JP 2020552294 A JP2020552294 A JP 2020552294A JP 2021519763 A5 JP2021519763 A5 JP 2021519763A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- rdna sequence
- bile acids
- secondary bile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650002P | 2018-03-29 | 2018-03-29 | |
| US62/650,002 | 2018-03-29 | ||
| PCT/US2019/025010 WO2019191694A1 (en) | 2018-03-29 | 2019-03-29 | Compositions and methods for treating inflammatory bowel diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021519763A JP2021519763A (ja) | 2021-08-12 |
| JP2021519763A5 true JP2021519763A5 (enExample) | 2022-04-06 |
Family
ID=66429534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020552294A Pending JP2021519763A (ja) | 2018-03-29 | 2019-03-29 | 炎症性腸疾患を治療するための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210121505A1 (enExample) |
| EP (1) | EP3773643A1 (enExample) |
| JP (1) | JP2021519763A (enExample) |
| KR (1) | KR20200138333A (enExample) |
| CN (1) | CN112118852A (enExample) |
| AU (1) | AU2019245430A1 (enExample) |
| BR (1) | BR112020019979A2 (enExample) |
| CA (1) | CA3095402A1 (enExample) |
| MX (1) | MX2020010177A (enExample) |
| WO (1) | WO2019191694A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018318132B2 (en) | 2017-08-14 | 2025-06-26 | Seres Therapeutics, Inc. | Compositions and methods for treating cholestatic disease |
| EP3703720A1 (en) | 2017-10-30 | 2020-09-09 | Seres Therapeutics, Inc. | Compositions and methods for treating antibiotic resistance |
| MX2022002949A (es) | 2019-09-24 | 2022-04-06 | Prolacta Bioscience Inc | Composiciones y metodos para el tratamiento de enfermedades inflamatorias e inmunes. |
| KR102341323B1 (ko) * | 2020-07-07 | 2021-12-21 | 한국원자력의학원 | 미세플라스틱 노출에 의해 유도되는 뇌질환 예후 예측용 바이오마커 조성물 및 이를 이용한 예후 예측방법 |
| IL300573A (en) | 2020-08-14 | 2023-04-01 | Prolacta Bioscience Inc | Breast milk oligosaccharide compositions for use with bacteriotherapy |
| KR102337993B1 (ko) * | 2021-10-27 | 2021-12-14 | 주식회사 바이오뱅크힐링 | 클로스트리디움 렙텀 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| CN115478031B (zh) * | 2022-09-28 | 2025-04-18 | 中国科学院深圳先进技术研究院 | 防治炎症性肠病的胆汁酸代谢菌及其应用 |
| WO2025244478A1 (ko) * | 2024-05-24 | 2025-11-27 | 서울대학교병원 | 클로스트리디움 렙텀 균주의 염증성장질환 예방, 치료 및 진단 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2013035804A1 (ja) * | 2011-09-08 | 2015-03-23 | カルピス株式会社 | 芽胞形成菌の発芽誘起方法 |
| JP5921894B2 (ja) * | 2012-01-20 | 2016-05-24 | アサヒカルピスウェルネス株式会社 | 腸内酪酸産生菌増加剤 |
| US11185562B2 (en) * | 2013-02-04 | 2021-11-30 | Seres Therapeutics, Inc. | Compositions and methods for inhibition of pathogenic bacterial growth |
| MA41020A (fr) * | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| EP4233884A3 (en) * | 2015-11-24 | 2023-10-04 | Seres Therapeutics, Inc. | Designed bacterial compositions |
| JP6624903B2 (ja) * | 2015-11-25 | 2019-12-25 | 学校法人東京理科大学 | 消毒剤及び消毒方法 |
| WO2017160711A1 (en) * | 2016-03-14 | 2017-09-21 | Holobiome, Inc. | Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system |
| US11786562B2 (en) * | 2016-04-19 | 2023-10-17 | Genome Research Limited | Bacteriotherapy |
| ES2960053T3 (es) * | 2016-06-14 | 2024-02-29 | Vedanta Biosciences Inc | Tratamiento de infección por Clostridium difficile |
| AU2018318132B2 (en) * | 2017-08-14 | 2025-06-26 | Seres Therapeutics, Inc. | Compositions and methods for treating cholestatic disease |
| EP3703720A1 (en) * | 2017-10-30 | 2020-09-09 | Seres Therapeutics, Inc. | Compositions and methods for treating antibiotic resistance |
-
2019
- 2019-03-29 MX MX2020010177A patent/MX2020010177A/es unknown
- 2019-03-29 US US17/043,545 patent/US20210121505A1/en not_active Abandoned
- 2019-03-29 CN CN201980030991.9A patent/CN112118852A/zh active Pending
- 2019-03-29 CA CA3095402A patent/CA3095402A1/en active Pending
- 2019-03-29 BR BR112020019979-6A patent/BR112020019979A2/pt unknown
- 2019-03-29 KR KR1020207031101A patent/KR20200138333A/ko not_active Ceased
- 2019-03-29 EP EP19722309.2A patent/EP3773643A1/en not_active Withdrawn
- 2019-03-29 AU AU2019245430A patent/AU2019245430A1/en not_active Abandoned
- 2019-03-29 JP JP2020552294A patent/JP2021519763A/ja active Pending
- 2019-03-29 WO PCT/US2019/025010 patent/WO2019191694A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Poritz et al. | Remicade® does not abolish the need for surgery in fistulizing Crohn’s disease | |
| JP2021524476A5 (enExample) | ||
| JP2022166039A (ja) | 肝内胆汁うっ滞および関連肝疾患の治療 | |
| Tremaine | Gastroduodenal Crohn's disease: medical management | |
| JP2000507938A (ja) | 結腸直腸の化学的保護のためのウルソデオキシコール酸化合物及びｎｓａｉｄの組合せ | |
| Liu et al. | The farnesoid X receptor agonist tropifexor prevents liver damage in parenteral nutrition‐fed neonatal piglets | |
| Mazzuoli et al. | Forty-eight months outcomes of teduglutide treatment in adult stable patients with short bowel syndrome and home parenteral nutrition dependence: A real-world Italian single-center observational cohort study | |
| Nikolaidis et al. | Small-duct primary sclerosing cholangitis. A single-center seven-year experience | |
| EP3538132B1 (en) | Rectal insulin for treatment of inflammatory bowel diseases | |
| Chen et al. | Statin therapy and gut microbiota | |
| Safarovich | Influence of intestinal microflora on the development of gallstone disease (literature review) | |
| Georganas et al. | Relapsing Wegner's granulomatosis: Successful treatment with cyclosporin-A | |
| WO2022068077A1 (zh) | 石胆酸用于制备缓解肝纤维化的药物中的应用 | |
| Ruocco et al. | Crohn's disease and its mucocutaneous involvement | |
| Rather et al. | Ulcerative colitis and probiotics: An overview. | |
| CN107530361A (zh) | 用于调节骨密度的方法 | |
| CN117625588A (zh) | 一种治疗非酒精性脂肪肝的活菌复合物 | |
| Ong et al. | Sclerosing cholangitis in children with inflammatory bowel disease | |
| EP1305012A2 (en) | A method for treating celiac disease | |
| CN102178684A (zh) | 牛磺鹅去氧胆酸在防治糖皮质激素类药物不良反应的应用 | |
| CN102178683A (zh) | 牛磺鹅去氧胆酸在保护消化道功能上的应用 | |
| JP2008533186A (ja) | 腸炎治療のためのマクロライド類の使用 | |
| Derbak et al. | Correction of Intestinal Dysbiosis in Patients with Chronic Hepatitis C against the Background of non-alcoholic Fatty Liver Disease | |
| Modirrousta et al. | The Effect of Exercise Training and Probiotic Supplementation on TGF-β gene Expression and Liver Factors in Male Rats with Cholestasis | |
| Lexmond et al. | interruption of the enterohepatic circulation in patients with PFIC1 and PFIC2 who proved unresponsive to either treatment alone |